XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT),a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, along with its German diagnostics development partner, 3a-diagnostics GmbH (“3a”), has received European approval of its point-of-care SARS-CoV-2 RT-PCR test system, called Covid-ID Lab. Covid-ID Lab is now registered as a commercial in vitro diagnostic (CE-IVD) test in Europe, and plans are in place to launch the product in Europe in April 2021. XPhyto is exploring options with various potential distribution and wholesale partners as well as potential licensees. The test offers high sensitivity, high specificity, and high robustness, with no impact on results from minor changes in process parameters. In addition to detecting COVID-19, specificity of 100% against 19 pathogens of serious respiratory infections was demonstrated on a respiratory verification panel. In testing, the systems showed precision through evaluation of variance of the analysis results due to random deviations, a repeatability/intra-assay precision. “Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” said XPhyto director and CEO Hugh Rogers in the press release. “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings.”
To view the full press release, visit https://ibn.fm/xqrEC
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
